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Background: This study examined demographic profile continuation rates and reasons for 
removal among Implanon® users accessing two family planning clinics in Queensland, 
Australia.  
Study Design: A retrospective chart audit of 976 women who attended for for implant 
insertion over a three year period between May 2001 and May 2004. 
Results: Continuation rates showed that at six months after insertion, 94% of women 
continued, 74% continued at one year, and 50% continued at two years. Metropolitan women 
were more likely than rural women to discontinue use because of dissatisfaction with 
bleeding patterns. Cox regression analysis showed that those attending the regional clinic 
experienced significantly shorter time to removal. 
Conclusions: Implanon® continuation rates and reasons for removal differ between clinics in 
metropolitan and rural locations. A cooling off period did not affect the likelihood of 
continuation with Implanon®. Pre-insertion counselling should emphasise potential changes 
in bleeding patterns. 
1. Introduction 
 
The progestogen contraceptive implant, Implanon®, became available in Australia in May 
2001. Many contraceptive options have historically bypassed the small Australian market, so 
this new method was rapidly embraced enthusiastically by women and doctors. Its potential 
advantages over available methods included high efficacy, the need for minimal maintenance, 
absence of oestrogen and rapid return to fertility after discontinuation. In the two years 
following its introduction around 10 000 doctors were trained in the use of the implant and 
almost 160 000 implants were inserted [1]. 
 
Although Implanon® is generally well tolerated, clinical trials have indicated that a 
proportion of women will discontinue use because of unacceptable side-effects, particularly 
frequent and/or prolonged irregular bleeding; with marked variations between countries. 
Discontinuation rates within the first 2 years of use were as high as 31% in Europe, Canada, 
Chile and Hungary to less than one percent of women in South East Asia [2, 3].  
 
Counselling women on expected bleeding patterns has been shown to improve continuation 
rates for injectable and implantable progestogen contraceptives [4-9]. Acceptability of 
bleeding pattern changes or other side effects is probably only ever truly evidenced in 
continuation rates in the real life setting. Several audits [10-13] have examined data from UK 
clinics and found lower continuation rates than in clinical trials, although the rates were 
sufficiently high to support the use of implants as a cost effective method of contraception 
[11]. An Australian study suggested that about one third of users had the implant removed 
within 12 months of insertion [1]. 
 
To date there is only limited published data on the patterns of use and continuation rates of 
Implanon® users in Australia. This paper determines continuation rates and rationale for 
discontinuation among 976 clients attending two Family Planning Queensland (FPQ) clinics 
over a three year period. 
 
2. Methods and materials 
 
This study was designed to assess the demographic profile, the continuation rates, the lost to 
follow-up rate and reasons for removal among Implanon® users accessing two community 
based family planning clinics in Queensland, Australia. The study was undertaken as an 
internal quality assurance project and therefore did not require clearance by a human research 
ethics committee [14]. In May 2007 a retrospective chart audit was conducted of all clients 
attending the clinics for implant insertion and/or removal over a five year period between 
May 2001 and May 2006. The data presented in this paper pertains to the women for whom 
three years (the recommended duration of use for Implanon ® use) had been completed at the 
time of audit. FPQ provides around 24,000 sexual and reproductive health services to around 
16,000 clients per annum across six centres in the state. The clinics chosen for the audit had 
the highest number of clients accessing clinical services – one of these is in Brisbane, the 
state capital (population 1.6 million) and the other is in a regional city (population 90,000) 
200 km from Brisbane.  
 
Case notes for all women attending the two clinics during the specified timeframe were 
reviewed for information relating to age, parity, indigenous status, country of birth, language 
spoken, weight, baseline menstrual pattern, most recent contraceptive use, date of Implanon® 
insertion, subsequent clinical consultations, reported side-effects, discontinuation and 
rationale for removal. Women are routinely contacted by mail one to three months before the 
due date of removal and reminded about the need to remove the implant. No other attempt 
was made to contact women who had not returned to the clinic. 
 
A total of 976 women had Implanon® inserted at the 2 clinics between May 2001 and May 
2004. There were 209 women who had not attended the clinic since insertion and these 
women had only baseline data and were considered lost to follow up. The remaining 767 
women were included in the survival analyses. In this group, 597 had a recorded removal. 
The date of removal was recorded for 580 while 17 had reported dissatisfaction with the 
implant but the date of removal was not documented. Among these 17 women a date of 
removal was estimated based on the last clinical visit. The remaining 170 women did not 
have a recorded removal during the follow-up period but had been seen in the clinic at one or 
more visits at which time their implant was still in situ and they are therefore included in the 
survival analyses. These data were used in the analysis as shown in Fig. 1. 
 
Examination of the socio-demographic and clinical information of women for whom 
complete data was available showed few significant differences compared to the 209 women 
who were lost to follow up. Specifically, the two groups did not differ by age, country of 
birth or previous pregnancies.  However, differences were noted with regard to baseline 
contraceptive use and menstrual history. Specifically, women for whom there was complete 
data were more likely to have regular menstrual cycles (81% compared with 73%) and to 
have used some other form of contraception at the time of insertion. There was no significant 
difference in the proportion of women lost to follow up between the metropolitan and 
regional clinics. 
 
Data were analysed using SPSS version 15.0 (SPSS, 2006). Demographic and contraceptive 
history information was tabulated for the sample. Differences between discrete variables were 
tested with χ2 test while comparisons between normally distributed continuous variables used 
t-test. Continuation rates were analysed using Kaplan Meier survival analysis. Cox regression 
was used to adjust for age, parity, geographic region and whether the implant was inserted on 
the day of assessment. 
 
3. Results 
 
Socio-demographic characteristics and other relevant clinical information including previous 
contraceptive use of the women attending either the metropolitan or regional family planning 
clinic are summarised in Table 1. Women attending the metropolitan clinic for Implanon® 
were generally older than women attending the regional clinic (M=27.4, SD=72, M=25.7, 
SD=8.0, t973=3.48, p <0.01) and less likely to be Australian born. Women from the 
metropolitan clinic reported fewer pregnancies and fewer live births than women from the 
regional clinic. The metropolitan sample was also more likely to report contraceptive use 
prior to commencing Implanon®. The type of contraceptive use by women differed by clinic 
location. Specifically, regional women were more likely to have used the combined oral 
contraceptive while women from the metropolitan clinic were more likely to report condom 
use. 
 
FPQ practice policy is that women requesting Implanon® attend an assessment visit where 
suitability for the implant method is assessed, information and prescription provided and a 
suitable time to return for insertion is discussed, allowing a “cooling off” between 
information provision and insertion. However for a range of clinical and practical reasons, the 
implant will sometimes be inserted on the same day as the assessment. The average time 
between the assessment consultation and insertion was 15 days (SD = 20 days).  Just over a 
quarter (27%; N = 260/976) of women had their implant inserted at the time of the 
assessment visit.  
 
Kaplan-Meier survival analysis was performed to provide estimated continuation rates to 
three years, based on those 767 women with follow-up data. The survival curve is depicted in 
Fig. 2 and both the observed and the estimated cumulative continuation rates are presented in 
Table 2. At 6 months after insertion, 94% of women had Implanon® in-situ. Continuation 
rates showed that 74% continued at one year, 61% continued at one and a half years and 50% 
continued at two years. Only a small proportion of the sample (1.2%) continued beyond the 
recommended three years after insertion. Nearing the time of removal (2.5 years) around 42% 
of the sample was still using Implanon®. In over a quarter of known removals (28%; N = 
164/597), women continued with the method, that is had a new implant inserted on the day of 
removal. 
 
Reasons for premature discontinuation (defined as discontinuation at less than 2.5 years after 
insertion) of Implanon® were obtained from clinical case notes. Data are presented in Table 
3. There were no pregnancies recorded in the 767 women who had an implant inserted at 
FPQ for whom follow up information is available. Metropolitan women were significantly 
more likely to discontinue use because of dissatisfaction with altered bleeding patterns alone, 
while regional women more commonly cited multiple reasons (including dissatisfaction with 
bleeding) for having the implant removed. Other common reasons for removal cited included 
desiring a pregnancy, contraception no longer being required, mood changes and weight gain. 
A proportion of women reported a considerable range of single ‘other’ reasons for 
discontinuation including low libido, pelvic pain, headaches, mastalgia, arm pain, dislike of 
hormones or light menstrual flow. These are combined under the category of ‘other’ in Table 
3. 
 
Table 4 shows Cox regression analysis examining the factors associated with survival time. 
Several variables were examined including the influence of age at insertion, parity (number 
of live births), clinic (metropolitan vs. regional clinics) and whether or not the insertion 
occurred on the same day as assessment. The clinic where Implanon® was inserted was the 
only significant covariate, with a hazard ratio of 0.77 (95% CI: 0.64 - 0.92). In other words, 
the location of the clinic significantly impacted survival time. Those who attended the 
regional clinic experienced significantly shorter survival times (or time to removal). 
However, survival time was not impacted by age, parity or a “cooling off period” between 
assessment and insertion. 
 
 
4. Discussion 
 
This study examined continuation rates of the contraceptive implant Implanon® and reasons 
for early discontinuation. As expected, lower continuation rates for the method were seen 
than those in clinical trials where overall > 80% were still using the implant at two years [3]. 
Strict inclusion criteria in clinical trials tend to bias towards a willingness to continue with 
regular follow up visits, free supplies and health services serving as positive reinforcement to 
continuation. Implanon® continuation rates in this Australian study of 74% at one year and 
50% at two years are consistent with findings from a review of evidence from real use 
settings in the UK and Europe which concluded that 20-25% and up to 44% of women will 
discontinue within one year and two years respectively [15]. Continuation rates at three years 
are more difficult to determine as implant users are generally advised to have routine implant 
removal before the three year expiry date. In this study 42% of women still had the implant in 
situ at 2.5 years and only 13% at three years; removal beyond 2.5 years was not considered 
early discontinuation. A study of 329 users of Implanon in Scotland [11] used 2 years 9 
months as an end point and found a comparable rate of 47% of women continuing with the 
implant at that point. At one year continuation rates are similar to those reported with 
intrauterine methods (73-91%) and higher than those for injectable (56%) and oral methods 
(32-68%) [15].  A detailed cost analysis of all contraceptive methods and concluded that 
despite their high initial purchase price implants are more cost effective than the combined 
oral contraceptive pill, even after one year of use [15]. In Australia, the government funds the 
majority of cost of an implant via the Pharmaceutical Benefits Scheme. The cost to women of 
the implant purchase is low and the same as, or less than, four months oral contraceptive pill 
supply; however there is no published cost analysis in the Australian setting of  other 
contraceptive methods. 
 
Bleeding pattern dissatisfaction was the commonest reason for premature discontinuation 
which is consistent with clinical trials and other audits [4, 13]. There were 168 out of 337 
(50.6%) women across both clinics who reported abnormal bleeding as the main reason for 
premature removal. The difference in recorded reasons for premature removal between the 
two clinics may explain the overall finding that clinic location was the only variable 
associated with survival time. In this study a “cooling off period” between information 
provision at a separate assessment visit and insertion was not found to alter the likelihood of 
continuation.  
 
This study has several methodological limitations. First, data were collected through a 
clinical audit and therefore the quality of data relied on information previously gathered 
during clinical consultations. In this study, data quality and consistency was related directly 
to the information that was recorded and then able to be retrieved from the clinical chart. 
Moreover, data relied on patient attendance and in some instances patients did not return after 
insertion. Overall, one-fifth (21%, N = 209) of the charts contained incomplete information 
and data from these charts were excluded from the survival analyses. This may have 
influenced the quality of the data leading to bias [16]. The analysis suggested, however, that 
women for whom there were complete data, in many instances, did not differ from those who 
were lost to follow-up. Two exceptions were noted; women who were lost to follow-up were 
less likely to have regular baseline menstrual cycles or to have used contraception prior to 
Implanon® insertion.  
 
It is difficult to draw definite conclusions from this audit on the differences found between 
the two clinics in user demographics, continuation rates and reasons for removal. Whether 
this reflects differences in the clinic settings more generally, variations in initial counselling 
provided by the individual service providers, their management strategies with altered 
bleeding patterns, their clinical record keeping practices or  characteristics of women 
themselves in the two different settings is unclear and could be the subject of further research. 
Previous studies have found that improvements in continuation rates for long term methods  
may be associated with both provider characteristics [6, 17] and counselling strategies being 
tailored to a woman’s personal context [8].  
 
Despite the limitations associated with the data collection method, this audit provided an 
opportunity for Family Planning Queensland to review current clinical practices and the 
information provided to patients when considering Implanon® as a contraceptive choice; 
specifically on expected continuation rates and common reasons for premature removal in the 
Australian setting. Policies around the timing of assessment and insertion visits will now 
recognize that if clinically appropriate, inserting an implant on the day of assessment (with no 
interval “cooling off period” to consider the information) is not associated with premature 
discontinuation. The audit also provides local data for other doctors in Australia to include in 
their counselling of women about the method. 
 
Overall, this study found that Implanon® has continuation rates in Australia very similar to 
settings in Europe and the United Kingdom. These continuation rates are higher than those 
for injectable and oral hormonal methods, which combined with its low failure rate and 
minimal maintenance makes it a viable and cost effective method to be offered to women. 
However, a proportion of women continue to have the implant removed, most often due to 
altered bleeding patterns. This supports the need for pre-insertion counselling to specifically 
emphasise the potential changes in bleeding patterns that may be expected from this form of 
contraception. 
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Figure 1. Flow chart showing number of insertions, loss to follow up, and women eligible for 
inclusion in the survival analysis. 
 Figure 2.  Survival analysis curve for Implanon® users over three years 
 
Table 1. Socio-demographic characteristics and past contraceptive use of women attending 
two different family planning clinics in Queensland, Australia 
 Metropolitan 
(N = 629*) 
Regional 
(N = 347†) 
χ2 p value 
  n %  n %   
Born in Australia 479 76 330 95 55.61 <0.01 
Pregnancies       
   0 260 44 137 41  9.67 0.05 
   1 130 22 56 17   
   2 96 16 72 22   
   3 53 9 31 9   
   4 or more 46 8 38 11   
Live Births       
   0 363 62 169 51 15.67 <0.01 
   1 83 14 48 14   
   2 96 16 73 22   
   3 28 5 25 8   
   4 or more 15 3 18 5   
Regular baseline menstrual 
cycle 
481 79 256 79 0.02 0.90 
Contraception at baseline       
   COCP 186 31 117 37 12.84 <0.01 
   Condoms 219 36 86 27   
   Other§ 118 19 53 17   
   Nil/Not required 85 14 63 20   
* Information on pregnancies and live births missing for 44 women, percentages based on N = 585; information 
on regular baseline menstrual cycle missing for 23, percentages based on N = 606; information on baseline 
contraception missing for 21, percentages based on N = 608.  
† Information on pregnancies missing for 13 women, percentages based on N = 334; information on live births 
missing for 14 women, percentages based on N = 333; information on regular baseline menstrual cycle missing 
for 23, percentages based on N = 324; information on baseline contraception missing for 28, percentages based 
on N = 319.  
§ includes 3.0% (n = 21) using “withdrawal” 
 
Table 2.  Estimated cumulative continuation rates (N = 597*) 
Time Number of 
discontinuations 
Cases 
remaining 
with 
Implanon 
Observed 
cumulative 
continuation 
rate 
Estimated 
cumulative 
continuation 
rate 
Standard 
Error of the 
estimated 
continuation 
rate 
6 
months 34 563 0.943 0.848 0.014 
1 year 157 440 0.737 0.691 0.018 
1.5 
years 233 364 0.610 0.596 0.019 
2 years 297 300 0.503 0.506 0.020 
2.5 
years 345 252 0.422 0.444 0.020 
3 years 521 76 0.127 0.139 0.015 
3.5 
years 593 4 0.007 0.008 0.004 
4 years 596 1 0.002 0.004 0.003 
* Estimated cumulative continuation rates based on Kaplan-Meier analysis of those 767 
women with follow-up data. 
Table 3.  Reasons for early discontinuation1  
Reason Metropolitan 
 
Rural  
 
p value 
 n  (%) n  (%)  
Excess bleeding only 109 56.2 57 41.3 0.01 
Multiple reasons, 
including bleeding 
12 6.2 34 24.6 < 0.01 
Desiring pregnancy only 16 8.2 10 7.2 0.74 
Mood changes only 16 8.2 3 2.2 0.02 
Contraception no longer 
required only 
9 4.6 7 5.1 0.86 
Multiple reasons, not 
including bleeding 
6 3.1 10 7.2 0.08 
Weight gain only 9 4.6 4 2.9 0.42 
Other 17 8.8 13 9.4 0.84 
1 N=332 women who discontinued early had a recorded reason for removal. Early discontinuation was defined 
as removal prior to 2.5 years. There were no pregnancies recorded in the women who had an implant inserted at 
FPQ for whom follow up information is available. 
 
 
 
Table 4. Cox proportional hazard regression analysis of discontinuation rates 
Variable Coefficient Hazard ratio 
(95% confidence interval) 
p value 
Age at insertion -0.01 0.99 (0.98 – 1.01) 0.42 
Parity -0.04 0.96 (0.88 – 1.04) 0.35 
Clinic location -0.27 0.76 (0.64 – 0.92) <0.01 
Insertion on day of assessment 0.01 1.00 (0.99 – 1.01) 0.65 
 
 
